-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

Benzinga·05/11/2026 11:04:21
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.